Core Insights - Quantum BioPharma Ltd. has signed an agreement with a leading contract development and manufacturing organization (CDMO) to manufacture an oral formulation of Lucid-MS, which will be used in the upcoming Phase 2 clinical trial for multiple sclerosis (MS) [1][3] - Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound that has shown potential in preclinical models to prevent demyelination, a key characteristic of MS [2][4] - The company is preparing an Investigational New Drug (IND) application with the FDA as part of its clinical development strategy for Lucid-MS [3] Company Overview - Quantum BioPharma is focused on developing innovative therapies for neurodegenerative disorders and metabolic disorders, with a portfolio that includes drug candidates at various stages of development [4] - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc., which is involved in the development of a product called unbuzzd™, and has a royalty agreement that includes 7% of sales until total payments reach $250 million, after which the royalty will drop to 3% [4] - Quantum BioPharma also maintains strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [4]
Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial